Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
January 24, 2014
Systemic therapeutic approaches to advanced thyroid cancers
Michael E Menefee, Robert C Smallridge, Keith C Bible
American Journal of Cancer Research
|
August 27, 2013
Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma
Christina A von Roemeling, Laura A Marlow, William P Kennedy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2017
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
Maria E Cabanillas, Jonas A de Souza, Susan Geyer, et al.
Investigational New Drugs
|
June 8, 2019
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma
Hao Xie, Jun Yin, Manisha H Shah, et al.
Molecular Cancer Therapeutics
|
July 25, 2012
Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers
Simon J Cooper, Christina A von Roemeling, Kylie H Kang, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 19, 2020
Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy
Nicole M Iñiguez-Ariza, Sina Jasim, Mabel M Ryder, et al.
The Lancet. Oncology
|
September 21, 2010
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C Bible, Vera J Suman, Julian R Molina, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 10, 2012
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer
Keith C Bible, Vera J Suman, Michael E Menefee, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 11, 2014
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H
Keith C Bible, Vera J Suman, Julian R Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2017
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
Andrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
January 24, 2014
Systemic therapeutic approaches to advanced thyroid cancers
Michael E Menefee, Robert C Smallridge, Keith C Bible
American Journal of Cancer Research
|
August 27, 2013
Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma
Christina A von Roemeling, Laura A Marlow, William P Kennedy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2017
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
Maria E Cabanillas, Jonas A de Souza, Susan Geyer, et al.
Investigational New Drugs
|
June 8, 2019
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma
Hao Xie, Jun Yin, Manisha H Shah, et al.
Molecular Cancer Therapeutics
|
July 25, 2012
Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers
Simon J Cooper, Christina A von Roemeling, Kylie H Kang, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 19, 2020
Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy
Nicole M Iñiguez-Ariza, Sina Jasim, Mabel M Ryder, et al.
The Lancet. Oncology
|
September 21, 2010
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C Bible, Vera J Suman, Julian R Molina, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 10, 2012
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer
Keith C Bible, Vera J Suman, Michael E Menefee, et al.
The Journal of Clinical Endocrinology and Metabolism
|
March 11, 2014
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H
Keith C Bible, Vera J Suman, Julian R Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2017
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
Andrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, et al.
Page
of 2